MEKanistic Therapeutics
MEKanistic is innovating cancer therapies by advancing a novel class of selective kinase inhibitors rationally designed to target both EGFR and PI3K with a single molecule. This breakthrough design expands the therapeutic window while avoiding inherent toxicity challenges of multi-compound treatments. Preclinical studies of its lead drug MTX-531 show a high incidence of tumor regression with dramatically reduced toxicity.
